Prostate & Breast Cancer- New Treatments & Developmental Progres

SUMMARY

Introduction

The treatment for breast and prostate cancer are under intense progress. Cancer of the prostate is the second most frequently diagnosed cancer in men in the US and approximately 3 million women in the US are living with breast cancer. Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. Newly approved drugs are showing increased sale figures, and several of them are reaching for broader indications. So, the trend of continuously increasing revenues is expected for drugs presenting reliable clinical data to support their successful progress.

Research and analysis highlights

In the report "Prostate & Breast Cancer - New Treatments & Developmental Progress" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate & breast cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified approximately 200 drug candidates in clinical stage of development and more than 125 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in these markets and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

• Thorough examination of status and impact of several novel drugs in development
• Discussion of the challenges in current and future treatment strategies
• Anticancer pipeline of most companies in the field

Key reasons to read this report

• Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast and prostate cancer R&D, and the results of clinical trials to date
• Gain insight into the current challenges and commercial opportunities associated with breast and prostate cancer therapy
• Two hundred high quality references

TABLE OF CONTENTS

1 Executive Summary

2 Methodology

3 Table of Contents

• 3.1 List of Boxes
• 3.2 List of Tables

4 Prostate Cancer

• 4.1.1 Introduction
• 4.1.2 Disease Definitions
• 4.1.3 Etiology & Pathophysiology
• 4.1.4 Epidemiology
• 4.1.5 Prognosis
• 4.2 Current Treatment Strategies
  • 4.2.1 Localized Disease
    • 4.2.1.1 Locally Advanced Prostate Cancer
  • 4.2.2 Metastatic Prostate Cancer
    • 4.2.2.1 Hormone-Sensitive Metastatic Prostate Cancer
    • 4.2.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
• 4.3 Progress in Current Treatment Strategies
  • 4.3.1 Hormone Modulators
  • 4.3.2 Chemotherapy
• 4.4 Key Therapeutic Strategies for Future Therapies
  • 4.4.1 Therapeutic Type, Targets & Mechanisms
• 4.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
  • 4.5.1 Hormone Modulators
  • 4.5.2 Protein Kinase Inhibitors
  • 4.5.3 Apoptotic Inducers
  • 4.5.4 Immunotherapy
  • 4.5.5 DNA Binding
  • 4.5.6 Other
• 4.6 Current Drug Development: The Early Stage Pipeline
  • 4.6.1 Epothilones
  • 4.6.2 Protein Kinse Inhibitors
  • 4.6.3 Other
  • 4.6.4 Chemotherapy

5 Breast Cancer

• 5.1 Introduction
  • 5.1.1 Disease Definitions
  • 5.1.2 Etiology
  • 5.1.3 Epidemiology
  • 5.1.4 Prognosis
• 5.2 Current Treatment Strategies
  • 5.2.1 Localized Disease
  • 5.2.2 Advanced Disease
• 5.3 Progress in Current Treatment Strategies
  • 5.3.1 Hormone Based Therapies
  • 5.3.2 Antibodies
  • 5.3.3 Chemotherapy
• 5.4 Key Therapeutic Strategies for Future Therapies
  • 5.4.1 Therapeutic Type, Targets & Mechanisms
• 5.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
  • 5.5.1 The Epothilones
  • 5.5.2 Cell Cycle & Apoptosis
  • 5.5.3 Protein Kinase Inhibitors
  • 5.5.4 Immunotherapy
• 5.6 Current Drug Development: The Early Stage Pipeline
  • 5.6.1 DNA Targeting
  • 5.6.2 FTIs
  • 5.6.3 Antisense
  • 5.6.4 New Hormone Modulators
  • 5.6.5 Other
• 5.7 Disclaimer
  • 5.7.1 Liability
  • 5.7.2 Completeness

6 Drug Index

7 Company Index

List of Boxes

• Box 1: The Eastern Cooperative Oncology Group Study
• Box 2: Southwest Oncology Group Study 99-16 Design
• Box 3: TAX 327 Study Design
• Box 4: Quick Facts - Toremifene
• Box 5: Quick Facts - Bevacizumab
• Box 6: Quick Facts - Genasense
• Box 7: Quick Facts - R-flurbiprofen
• Box 8: Quick Facts - Exisulind
• Box 9: Quick Facts - Provenge
• Box 10: Quick Facts - GVAX
• Box 11: Quick Facts - Satraplatin
• Box 12: Quick Facts - Vapreotide
• Box 13: Quick Facts - DCVax
• Box 14: Ongoing Phase III Studies Anastrozole
• Box 15: Ongoing Phase III Studies Letrozole
• Box 16: Ongoing Phase III Studies Exemestane
• Box 17: Ongoing Phase III Studies Goserelin
• Box 18: Ongoing Phase III Studies Fulvestrant
• Box 19: Ongoing Phase III Studies Trastuzumab
• Box 20: Quick Facts - BMS-247550
• Box 21: Quick Facts - Temsirolimus
• Box 22: Quick Facts - SDX-105
• Box 23: Quick Facts - 4HPR
• Box 24: Quick Facts - Lapatinib
• Box 25: Quick Facts - Bevacizumab
• Box 26: Quick Facts - Theratope
• Box 27: Erlotinib
• Box 28: Gefitinib
• Box 29: Imatinib
• Box 30: Pemetrexed
• Box 31: NX473
• Box 32: Lonafarnib
• Box 33: Tipifarnib
• Box 34: Bortezomib
• Box 35: Arzoxifene
• Box 36: Patupilone
• Box 37: KOS-862

List of Tables

• Table 1: The TNM System
• Table 2: Lifestyle factors
• Table 3: Historical Summary of Clinical Studies on Patients with Late Stage Disease
• Table 4: Short Facts Bicalutamide
• Table 5: Short Facts Flutamide
• Table 6: Short Facts Goserelin
• Table 7: Short Facts Histrelin
• Table 8: Short Facts Lanreotide
• Table 9: Short Facts Leuprolide
• Table 10: Short Facts Nilutamide
• Table 11: Short Facts Abarelix
• Table 12: Short Facts Mitoxantrone
• Table 13: Short Facts Carboplatin
• Table 14: Short Facts Docetaxel
• Table 15: Short Facts Estramustine
• Table 16: Summary of Recent Clinical Studies on Patients with Late Stage Disease
• Table 17: Ongoing Late Stage Clinical Studies
• Table 18: Cancer Immunotherapy Strategies
• Table 19: Near Term Progress Toremifene
• Table 20: Near Term Progress Bevacizumab
• Table 21: Near Term Progress Oblimersen
• Table 22: Near Term Progress R-flurbiprofen
• Table 23: Near Term Progress Exisulind
• Table 24: Near Term Progress APC8015
• Table 25: Near Term Progress GVAX
• Table 26: Near Term Progress Satraplatin
• Table 27: Summary of Prostate Cancer Late Stage Pipeline
• Table 28: Epothilone
• Table 29: Ixabepilone
• Table 30: PTK/ZK
• Table 31: Imatinib
• Table 32: Bortezomib
• Table 33: Sorafenib
• Table 34: Arsenic trioxide
• Table 35: Retinoic Acid
• Table 36: Paclitaxel
• Table 37: Doxorubicin
• Table 38: Summary of Prostate Cancer Early Stage Pipeline
• Table 39: The Stage System
• Table 40: Risk Factors
• Table 41: List of Approved Drugs and Their Mechanisms of Action.
• Table 42: Hormonal Treatment Strategies
• Table 43: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer
• Table 44: Treatment Options for Women With Axillary Node-Positive Breast Cancer
• Table 45: Chemotherapy Drugs and Regimen
• Table 46: Summay of Drugs Involved in Breast Cancer Therapy
• Table 47: Short Facts Tamoxifen
• Table 48: Short Facts Anastrozole
• Table 49: Short Facts Letrozole
• Table 50: Short Facts Exemestane
• Table 51: Short Facts Goserelin
• Table 52: Short Facts Fulvestrant
• Table 53: Short Facts Trastuzumab
• Table 54: Cancer Immunotherapy Strategies
• Table 55: Progress on Ixabepilone
• Table 56: Progress on CCI-779
• Table 57: Progress on Fenretinide
• Table 58: Progress on Lapatinib
• Table 59: Progress on Bevacizumab
• Table 60: Progress on Theratope
• Table 61: Summary of Mid-Stage to Late stage Investigational Agents Under Development
• Table 62: Summary of Breast Cancer Early Stage Pipeline